A Parallel Group Treatment, Phase 2a, Double-blind, Two-arm Study to Investigate the Efficacy and Safety of Farudodstat Tablets Compared with its Placebo in Male or Female AlopeciaAreata Participants Aged 18 Years and Older with 50% or Greater Scalp Hair Loss

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- at least 18 years old - weight at least 40 kg (88 lbs) - severe or very severe Alopecia Areata (AA) - contact study staff for additional criteria for AA

Exclusion Criteria:

- history of androgenic alopecia or female pattern hair loss prior to AA or other types of hair loss - history or presence of hair transplants - other scalp disease that may impact AA assessment or require topical treatment (including, but not limited to scalp psoriasis, seborrheic dermatitis, actinic keratosis)

Conditions & Interventions

Interventions:
Drug: Farudodstat, Drug: Placebo
Conditions:
Dermatology (Skin, Hair & Nails)
Keywords:
Alopecia Areata, Hair loss

More Information

Description: The main purpose of the study is to see whether farudodstat, taken orally for 12 weeks, can help people with alopecia areata and to find out if farudodstat is safe and tolerable when compared to placebo. The placebo is a pill that looks like farudodstat tablet but has no drug or other active ingredient in it.
Study Contact: Dermatology Study - dermresearch@umn.edu
Principal Investigator: Maria Hordinsky
IRB Number: SITE00001917